Scientific publications
A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.
| Project | Indication | ||||
ODM-203(targeted FGFR+VEGFR inhibitor) |
Solid tumours |
||||
|
Congress posters ESMO 2018
Cholangiocarcinoma Foundation Annual Conference 2017
Scientific articles Holmström et al; Mol Can Ther |
19-23 October 2018
1-3 February 2017
9 October 2018 |
|
|||
ODM-207(BET protein inhibitor) |
Cancer |
||||
|
Congress posters AACR Annual Meeting 2019
EORTC 2018
AACR Annual Meeting 2018
Conference
AACR Annual Meeting 2017 |
29 March - 4 April 2019
13-16 November 2018
14-18 April 2018
1-5 April 2017 |
Targeting cancer with a novel BET bromodomain inhibitor
|
|||
ODM-208(CYP11A1 inhibitor) |
Prostate cancer (CRPC) |
||||
|
Congress posters ENDO 2019
ESMO 2018
The 24th Annual PCF Scientific Retreat
ESMO 2017
|
23-26 March 2019
19-23 October 2018 8-10 February 2018
8-12 September 2017 |
CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
CYP11A1 inhibitor as a therapeutic approach for the treatment of castration resistant prostate cancer
CYP11A1 inhibitor as a threapeutic approach for the treatment of castration resistant prostate cancer
ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer |
|||
ODM-104(more effective COMT inhibitor) |
Parkinson's disease |
||||
|
Congress posters MDS 2018
EAN 2018
AAN 2018
|
5-9 October 2018
16-19 June 2018
21-27 April 2018
|
ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subject
ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
|
|||
ODM-109(oral levosimendan) |
ALS |
||||
|
Congress posters ALS / MND 20199
NEALS 2019
ENCALS 2019
ALS / MND 2018
NEALS 2018
ALS / MND 2017
|
4-6 December 2019
2-4 October 2019
15-17 May 2019
7-9 December 2018
2-4 October 2018
8-10 December 2017
|
Mechanism of action of the cardiovascular drug levosimendan in the management of ALS
Oral levosimendan for ALS: pharmacokinetic considerations
Biomarker analysis in oral levosimendan phase 2 clinical trial LEVALS
Biomarker analysis in oral levosimendan phase 2 clinical trial LEVALS
The REFALS-ES opel-label extension study of oral levosimendan (ODM-109)
Safety and tolerability of oral levosimendan
Oral levosimendan in ALS: the REFALS phase 3 study design
Oral levosimendan in ALS: the REFALS phase 3 study design
|
|||
|
|
|||||
|
|
|
||||
